SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya.
HIV/AIDS
Kenya
PWID
SARS-CoV-2 antibody
Sub-Saharan Africa
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
23 02 2023
23 02 2023
Historique:
received:
26
10
2022
accepted:
09
02
2023
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
In sub-Saharan Africa many people who inject drugs (PWID) are living with undiagnosed or untreated HIV and experience high levels of poverty and conditions that can contribute to worse outcomes from SARS-CoV-2 infection. Identifying the burden of SARS-CoV-2 infection in marginalized populations like PWID may contribute to controlling the pandemic. This is a nested cross-sectional study within an ongoing cohort study that recruits PWID living with HIV and their injecting and/or sexual partners at needle and syringe program sites and methadone clinics in Kenya. Blood samples were collected from consenting participants at enrollment to determine SARS-CoV-2 antibodies using a Platellia BioRad SARS-CoV-2 total antibody enzyme-linked immunosorbent assay. Baseline data were collected on HIV status, antiretroviral therapy and methadone adherence. We used logistic regression to identify factors associated with antibody positivity and descriptive statistics to report SARS-CoV-2 antibody prevalence. One thousand participants were enrolled between April and July 2021, of whom 323 (32.3%) were women and 677 (67.7%) were men. Median age of participants was 36 years (interquartile range: 30, 42). SARS-CoV-2 antibody positivity was found in 309 (30.9%) participants. Disruption in obtaining methadone service was reported by 106 (24.3%) of the participants. Men were significantly less likely than women to have SARS-CoV-2 antibodies (adjusted odds ratio [aOR] = 0.68, 95% confidence interval [CI] 0.51, 0.95; p < 0.01) Participants who reported a sexual or injecting partner diagnosed with SARS-CoV-2 were twofold more likely to have SARS-CoV-2 antibodies detected (aOR = 2.21, 95% CI 1.06, 4.58; p < 0.032). Living with HIV was not associated with presence of SARS-CoV-2 antibodies. The seroprevalence of SARS-CoV-2 of 30.9% in this cohort suggests high transmission rates within this population. SARS-CoV-2 seroprevalence was similar for people living with and without HIV. A large portion of this population was noted to have had disruption in access to harm reduction services.
Sections du résumé
BACKGROUND
In sub-Saharan Africa many people who inject drugs (PWID) are living with undiagnosed or untreated HIV and experience high levels of poverty and conditions that can contribute to worse outcomes from SARS-CoV-2 infection. Identifying the burden of SARS-CoV-2 infection in marginalized populations like PWID may contribute to controlling the pandemic.
METHODS
This is a nested cross-sectional study within an ongoing cohort study that recruits PWID living with HIV and their injecting and/or sexual partners at needle and syringe program sites and methadone clinics in Kenya. Blood samples were collected from consenting participants at enrollment to determine SARS-CoV-2 antibodies using a Platellia BioRad SARS-CoV-2 total antibody enzyme-linked immunosorbent assay. Baseline data were collected on HIV status, antiretroviral therapy and methadone adherence. We used logistic regression to identify factors associated with antibody positivity and descriptive statistics to report SARS-CoV-2 antibody prevalence.
RESULTS
One thousand participants were enrolled between April and July 2021, of whom 323 (32.3%) were women and 677 (67.7%) were men. Median age of participants was 36 years (interquartile range: 30, 42). SARS-CoV-2 antibody positivity was found in 309 (30.9%) participants. Disruption in obtaining methadone service was reported by 106 (24.3%) of the participants. Men were significantly less likely than women to have SARS-CoV-2 antibodies (adjusted odds ratio [aOR] = 0.68, 95% confidence interval [CI] 0.51, 0.95; p < 0.01) Participants who reported a sexual or injecting partner diagnosed with SARS-CoV-2 were twofold more likely to have SARS-CoV-2 antibodies detected (aOR = 2.21, 95% CI 1.06, 4.58; p < 0.032). Living with HIV was not associated with presence of SARS-CoV-2 antibodies.
CONCLUSION
The seroprevalence of SARS-CoV-2 of 30.9% in this cohort suggests high transmission rates within this population. SARS-CoV-2 seroprevalence was similar for people living with and without HIV. A large portion of this population was noted to have had disruption in access to harm reduction services.
Identifiants
pubmed: 36823596
doi: 10.1186/s12954-023-00754-5
pii: 10.1186/s12954-023-00754-5
pmc: PMC9947430
doi:
Substances chimiques
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
21Subventions
Organisme : NIDA NIH HHS
ID : R01 DA043409
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
AIDS. 2021 Mar 15;35(4):F1-F10
pubmed: 33587448
JAMA Netw Open. 2021 Feb 1;4(2):e2037069
pubmed: 33533933
Lancet HIV. 2020 Aug;7(8):e554-e564
pubmed: 32473657
AIDS. 2021 Nov 15;35(14):2401-2404
pubmed: 34482354
South Afr J HIV Med. 2021 Apr 15;22(1):1220
pubmed: 33936793
J Urban Health. 2020 Dec;97(6):802-807
pubmed: 33005988
Science. 2021 Nov 19;374(6570):989-994
pubmed: 34618602
J Urban Health. 2005 Mar;82(1):151-61
pubmed: 15746385
HIV Med. 2021 May;22(5):372-378
pubmed: 33368966
Int J Infect Dis. 2021 Nov;112:25-34
pubmed: 34481966
Int J Drug Policy. 2014 May;25(3):363-71
pubmed: 24561223
J Med Virol. 2021 Feb;93(2):803-811
pubmed: 32667733
Harm Reduct J. 2021 May 10;18(1):52
pubmed: 33971892
BMJ Open. 2021 Apr 24;11(4):e041083
pubmed: 33895711
Drug Alcohol Rev. 2020 May;39(4):297-300
pubmed: 32445265
Wellcome Open Res. 2021 May 25;6:127
pubmed: 36187498
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Mol Psychiatry. 2021 Jan;26(1):30-39
pubmed: 32929211
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Connect (Tor). 2006;27(1):9-14
pubmed: 21796224
Int J Drug Policy. 2021 Jun;92:103127
pubmed: 33549464
Nat Commun. 2021 Jun 25;12(1):3966
pubmed: 34172732
Int J Drug Policy. 2020 Sep;83:102872
pubmed: 32713765
Aust N Z J Public Health. 2018 Oct;42(5):447-450
pubmed: 30035839
Clin Infect Dis. 2021 Oct 5;73(7):e1964-e1972
pubmed: 32905581